Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Buck Institute finds link between ApoE4 and anti-aging protein targeted by resveratrol in red wine

he major genetic risk factor for Alzheimer's disease (AD), present in about two-thirds of people who develop the disease, is ApoE4, the cholesterol-carrying protein that about a quarter of us are born with. But one of the unsolved mysteries of AD is how ApoE4 causes the risk for the incurable, neurodegenerative disease.

22 Oct 2013

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron Pharmaceuticals, Inc. today announced positive topline results for EYLEA® (aflibercept) Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO).

21 Oct 2013

Study aims to identify age-related changes in metabolic pathways

Have you ever wondered why young children can eat bags of Halloween candy and feel fine the next day - compared to adults who experience all sorts of agony following the same junk food binge? Evolution and a gene called Foxo may be to blame. Working in fruit flies, scientists at the Buck Institute have identified a mechanism that helps the flies adapt to changes in diet when they're young; they've discovered that same mechanism gets misregulated as the flies age, disrupting metabolic homeostasis, or balance.

16 Oct 2013

Possible topical treatment for age-related macular degeneration identified by Tufts researchers

Researchers from Tufts University School of Medicine and the Sackler School of Graduate Biomedical Sciences have identified a possible topical treatment for age-related macular degeneration in a study of mice that shows promise for clinical use.

10 Oct 2013

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

Allegro Ophthalmics, LLC, a company dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vascular eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to begin two Phase II clinical studies of ALG-1001.

10 Oct 2013

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, announced today that it has initiated a Phase 2 clinical trial to evaluate PRM-151, its lead product candidate, in patients with myelofibrosis.

10 Oct 2013

Healios K.K. successfully raised its target capital of 3 billion JPY (USD $30.6 million)

Healios K.K. (Headquarters: Tokyo, Japan; President and CEO: Hardy TS Kagimoto M.D.), a Japanese bioventure company at the forefront of developing innovative therapies utilizing human induced pluripotent stem cell (hiPSC) technology, is pleased to announce that it has successfully raised its target capital of 3 billion JPY (USD $30.6 million).

9 Oct 2013

Research roundup: Health law's effects on consumer spending; Mass. experience finds increased use of laparoscopic surgery

The authors find that average out-of-pocket spending is expected to decrease for all groups considered in the analysis, although decreases in out-of-pocket spending will be largest for those who would otherwise be uninsured.

5 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

2 Oct 2013

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

...

1 Oct 2013

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharmaceutical Industries Ltd., an international specialty pharmaceutical company focused on chronic diseases, through its subsidiary, and Intrexon Corporation, a leader in synthetic biology, today announced the formation of a joint venture to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide.

1 Oct 2013

Optic flow enables perception despite blur image

Blurred images that are unidentifiable as still pictures become understandable once the images are set in motion. That's because of a phenomenon called "optic flow"—which may be especially relevant as a source of visual information in people with low vision, reports a study 'With an Eye to Low Vision: Optic Flow Enables Perception Despite Image Blur' in the October issue of Optometry and Vision Science official journal of the American Academy of Optometry.

27 Sep 2013

New publication covers basic and advanced ophthalmic radiation therapy techniques

This publication, a conjoint effort by ocular oncologists and radiation oncologists, comprises ten chapters covering basic and advanced radiation therapy techniques followed by specific indications by location (uveal, retinal, orbital tumors, eyelid and conjunctival tumors) and complications of radiation therapy.

20 Sep 2013

Researchers identify gene mutation linked to age-related macular degeneration

An international team of researchers, led by scientists at The Genome Institute at Washington University School of Medicine in St. Louis and the University of Michigan School of Public Health in Ann Arbor, has identified a gene mutation linked to age-related macular degeneration (AMD), the leading cause of blindness in Americans over age 50.

17 Sep 2013

Drug used in patients for cancer treatment has beneficial effects on diabetes

A pair of studies by researchers at the Stanford University School of Medicine has identified a molecular pathway - a series of interaction among proteins - involved in the development of diabetes. Furthermore, they have found that a drug already approved for use in humans can regulate the pathway.

16 Sep 2013

New technique provides better understanding of factors causing Smith-Lemli-Opitz Syndrome

The first proteomic analysis of an animal model of a rare, sometimes deadly birth defect, Smith-Lemli-Opitz Syndrome (SLOS), has revealed that the molecular mechanisms that cause it are more complex than previously understood.

12 Sep 2013

Longer looks: Phenomenal growth of the Cleveland Clinic prompts hopes for the city; the bittersweet decision to donate organs

Delos M. "Toby" Cosgrove arrived at the Cleveland Clinic in 1975 as an "incredibly poor" 34-year-old dreaming of a life as a cardiac surgeon. … As the years passed he became well-known for pioneering the replacement of heart valves, eventually assuming the chair of the department of cardiothoracic surgery.

From Medtronic 5 Sep 2013

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO).

29 Aug 2013

AMD associated with impaired lysosomal autophagy, study finds

A new study published in the prestigious PLoS One journal changes our understanding of the pathogenesis of age-related macular degeneration. The researchers found that degenerative changes and loss of vision are caused by impaired function of the lysosomal clean-up mechanism, or autophagy, in the fundus of the eye.

22 Aug 2013

New drug-delivery strategy for central vision loss

Johns Hopkins biomedical engineers have teamed up with clinicians to create a new drug-delivery strategy for a type of central vision loss caused by blood vessel growth at the back of the eye, where such growth should not occur.

20 Aug 2013

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Buck Institute finds link between ApoE4 and anti-aging protein targeted by resveratrol in red wine

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Study aims to identify age-related changes in metabolic pathways

Possible topical treatment for age-related macular degeneration identified by Tufts researchers

Allegro receives FDA IND approval to initiate Phase II clinical studies of ALG-1001 in AMD, VMT patients

Promedior starts Phase 2 clinical trial to evaluate PRM-151 in patients with myelofibrosis

Healios K.K. successfully raised its target capital of 3 billion JPY (USD $30.6 million)

Research roundup: Health law's effects on consumer spending; Mass. experience finds increased use of laparoscopic surgery

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Sun Pharma, Intrexon Team Up To Target Ocular Diseases

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Optic flow enables perception despite blur image

New publication covers basic and advanced ophthalmic radiation therapy techniques

Researchers identify gene mutation linked to age-related macular degeneration

Drug used in patients for cancer treatment has beneficial effects on diabetes

New technique provides better understanding of factors causing Smith-Lemli-Opitz Syndrome

Longer looks: Phenomenal growth of the Cleveland Clinic prompts hopes for the city; the bittersweet decision to donate organs

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

AMD associated with impaired lysosomal autophagy, study finds

New drug-delivery strategy for central vision loss

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Macular Degeneration News and Research

Latest Macular Degeneration News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in